Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition

Rae Lynn Baldwin, Helmut Friess, Munehiro Yokoyama, Martha E. Lopez, Michael S. Kobrin, Markus W. Büchler, Murray Korc

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Transforming growth factor-β (TGF-β) receptors constitute a family of transmembrane proteins that bind TGF-β ligands. In this study we assessed the growth responsiveness to TGF-βI in pancreatic cancer cell lines and characterized the levels of expression of TGF-β receptors in these cell lines and in human pancreatic cancer tissues. COLO 357 cells were most sensitive to the growth inhibitory actions of TGF-βI, PANC-1 cells exhibited moderate sensitivity, Hs766T cells exhibited slight sensitivity and MIA PaCa-2 and T3M4 cells were resistant to TGF-βI. Only COLO 357 cells expressed high levels of ALK5, the major type I TGF-β receptor (TβRI). Hs766T and PANC-1 cells expressed high levels of SKRI, another TβRI subtype. Only MIA PaCa-2 cells did not exhibit the type II TGF-β receptor (Tβ-RII) transcript, whereas type III TGF-β receptor (Tβ-RIII) mRNA levels were elevated in this cell line and in HS766T cells. All the cell lines expressed TGF-βI, but TGF-β2 and TGF-β3 mRNA levels were variable. ALK5 and SKRI mRNA levels were 6.8- and 9-fold greater in the pancreatic tumors in comparison with the corresponding levels in the normal pancreas. However, in the cancer cells, ALK5 immunoreactivity was faint, whereas TβRII immunoreactivity was focal and intense. Conversely, in ductal cells adjacent to cancer cells ALK5 immunoreactivity was strong, whereas TβRII immunoreactivity was weak. Since ALK5 heterodimerization with TβRII is crucial for TGF-β-mediated signaling, our findings suggest that low levels of ALK5 in pancreatic cancer cells within a tumor may protect against growth inhibition.

Original languageEnglish (US)
Pages (from-to)283-288
Number of pages6
JournalInternational Journal of Cancer
Volume67
Issue number2
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Transforming Growth Factors
Pancreatic Neoplasms
Growth
Growth Factor Receptors
Cell Line
Messenger RNA
Neoplasms
Pancreas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Attenuated ALK5 receptor expression in human pancreatic cancer : Correlation with resistance to growth inhibition. / Baldwin, Rae Lynn; Friess, Helmut; Yokoyama, Munehiro; Lopez, Martha E.; Kobrin, Michael S.; Büchler, Markus W.; Korc, Murray.

In: International Journal of Cancer, Vol. 67, No. 2, 1996, p. 283-288.

Research output: Contribution to journalArticle

Baldwin, Rae Lynn ; Friess, Helmut ; Yokoyama, Munehiro ; Lopez, Martha E. ; Kobrin, Michael S. ; Büchler, Markus W. ; Korc, Murray. / Attenuated ALK5 receptor expression in human pancreatic cancer : Correlation with resistance to growth inhibition. In: International Journal of Cancer. 1996 ; Vol. 67, No. 2. pp. 283-288.
@article{b8ba286f24164920bd1fb48e70df8f40,
title = "Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition",
abstract = "Transforming growth factor-β (TGF-β) receptors constitute a family of transmembrane proteins that bind TGF-β ligands. In this study we assessed the growth responsiveness to TGF-βI in pancreatic cancer cell lines and characterized the levels of expression of TGF-β receptors in these cell lines and in human pancreatic cancer tissues. COLO 357 cells were most sensitive to the growth inhibitory actions of TGF-βI, PANC-1 cells exhibited moderate sensitivity, Hs766T cells exhibited slight sensitivity and MIA PaCa-2 and T3M4 cells were resistant to TGF-βI. Only COLO 357 cells expressed high levels of ALK5, the major type I TGF-β receptor (TβRI). Hs766T and PANC-1 cells expressed high levels of SKRI, another TβRI subtype. Only MIA PaCa-2 cells did not exhibit the type II TGF-β receptor (Tβ-RII) transcript, whereas type III TGF-β receptor (Tβ-RIII) mRNA levels were elevated in this cell line and in HS766T cells. All the cell lines expressed TGF-βI, but TGF-β2 and TGF-β3 mRNA levels were variable. ALK5 and SKRI mRNA levels were 6.8- and 9-fold greater in the pancreatic tumors in comparison with the corresponding levels in the normal pancreas. However, in the cancer cells, ALK5 immunoreactivity was faint, whereas TβRII immunoreactivity was focal and intense. Conversely, in ductal cells adjacent to cancer cells ALK5 immunoreactivity was strong, whereas TβRII immunoreactivity was weak. Since ALK5 heterodimerization with TβRII is crucial for TGF-β-mediated signaling, our findings suggest that low levels of ALK5 in pancreatic cancer cells within a tumor may protect against growth inhibition.",
author = "Baldwin, {Rae Lynn} and Helmut Friess and Munehiro Yokoyama and Lopez, {Martha E.} and Kobrin, {Michael S.} and B{\"u}chler, {Markus W.} and Murray Korc",
year = "1996",
doi = "10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B",
language = "English (US)",
volume = "67",
pages = "283--288",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Attenuated ALK5 receptor expression in human pancreatic cancer

T2 - Correlation with resistance to growth inhibition

AU - Baldwin, Rae Lynn

AU - Friess, Helmut

AU - Yokoyama, Munehiro

AU - Lopez, Martha E.

AU - Kobrin, Michael S.

AU - Büchler, Markus W.

AU - Korc, Murray

PY - 1996

Y1 - 1996

N2 - Transforming growth factor-β (TGF-β) receptors constitute a family of transmembrane proteins that bind TGF-β ligands. In this study we assessed the growth responsiveness to TGF-βI in pancreatic cancer cell lines and characterized the levels of expression of TGF-β receptors in these cell lines and in human pancreatic cancer tissues. COLO 357 cells were most sensitive to the growth inhibitory actions of TGF-βI, PANC-1 cells exhibited moderate sensitivity, Hs766T cells exhibited slight sensitivity and MIA PaCa-2 and T3M4 cells were resistant to TGF-βI. Only COLO 357 cells expressed high levels of ALK5, the major type I TGF-β receptor (TβRI). Hs766T and PANC-1 cells expressed high levels of SKRI, another TβRI subtype. Only MIA PaCa-2 cells did not exhibit the type II TGF-β receptor (Tβ-RII) transcript, whereas type III TGF-β receptor (Tβ-RIII) mRNA levels were elevated in this cell line and in HS766T cells. All the cell lines expressed TGF-βI, but TGF-β2 and TGF-β3 mRNA levels were variable. ALK5 and SKRI mRNA levels were 6.8- and 9-fold greater in the pancreatic tumors in comparison with the corresponding levels in the normal pancreas. However, in the cancer cells, ALK5 immunoreactivity was faint, whereas TβRII immunoreactivity was focal and intense. Conversely, in ductal cells adjacent to cancer cells ALK5 immunoreactivity was strong, whereas TβRII immunoreactivity was weak. Since ALK5 heterodimerization with TβRII is crucial for TGF-β-mediated signaling, our findings suggest that low levels of ALK5 in pancreatic cancer cells within a tumor may protect against growth inhibition.

AB - Transforming growth factor-β (TGF-β) receptors constitute a family of transmembrane proteins that bind TGF-β ligands. In this study we assessed the growth responsiveness to TGF-βI in pancreatic cancer cell lines and characterized the levels of expression of TGF-β receptors in these cell lines and in human pancreatic cancer tissues. COLO 357 cells were most sensitive to the growth inhibitory actions of TGF-βI, PANC-1 cells exhibited moderate sensitivity, Hs766T cells exhibited slight sensitivity and MIA PaCa-2 and T3M4 cells were resistant to TGF-βI. Only COLO 357 cells expressed high levels of ALK5, the major type I TGF-β receptor (TβRI). Hs766T and PANC-1 cells expressed high levels of SKRI, another TβRI subtype. Only MIA PaCa-2 cells did not exhibit the type II TGF-β receptor (Tβ-RII) transcript, whereas type III TGF-β receptor (Tβ-RIII) mRNA levels were elevated in this cell line and in HS766T cells. All the cell lines expressed TGF-βI, but TGF-β2 and TGF-β3 mRNA levels were variable. ALK5 and SKRI mRNA levels were 6.8- and 9-fold greater in the pancreatic tumors in comparison with the corresponding levels in the normal pancreas. However, in the cancer cells, ALK5 immunoreactivity was faint, whereas TβRII immunoreactivity was focal and intense. Conversely, in ductal cells adjacent to cancer cells ALK5 immunoreactivity was strong, whereas TβRII immunoreactivity was weak. Since ALK5 heterodimerization with TβRII is crucial for TGF-β-mediated signaling, our findings suggest that low levels of ALK5 in pancreatic cancer cells within a tumor may protect against growth inhibition.

UR - http://www.scopus.com/inward/record.url?scp=0029810920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029810920&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B

DO - 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B

M3 - Article

C2 - 8760600

AN - SCOPUS:0029810920

VL - 67

SP - 283

EP - 288

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -